Company intelligence / Profile preview

MedGenesis Therapeutix Inc.

Victoria, British Columbia, Canadamedgenesis.com ↗

Ownership: Private
Development stage: Phase 2

Overview

MedGenesis Therapeutix was a Canadian biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious neurological diseases. Its lead program involved delivering recombinant human GDNF directly into the brain using proprietary convection-enhanced delivery technology. The most advanced clinical results were from a Phase II trial in Parkinson's disease supported by grants from organizations such as The Michael J. Fox Foundation and Parkinson's UK. No recent clinical updates or ongoing programs are reported since at least late 2022.

Therapeutic areas: Neurology
Modalities: Recombinant proteinsDrug-device combination therapies
Industry: Biotech

Partnerships

The Michael J. Fox FoundationParkinson's UK

Beyond the preview

Go deeper on MedGenesis Therapeutix Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MedGenesis Therapeutix Inc..